	I.1. Consignor				I.2. IMSOC reference	I.2.a. Local refere	nce			
	Name									
	Address					I.3. Central Comp	etent Authority			
	Country		ISO Code			I.4. Local Compet	ent Authority			
nt	I.5. Consignee				I.6. Operator conducting assembly o establishment	perations independ	lently of an			
nei	Name				Name					
IL	Address				Address					
١sig	Country		ISO Code		Approval Number					
COL					Country	ISO Code				
of	I.7. Country of orig	gin		ISO Code	I.9. Country of destination		ISO Code			
Part I: Description of consignment	I.8. Region of origi	n		Code	I.10. Region of destination		Code			
rip	1.3. Region of diama			Coue	-		coue			
esc	I.11. Place of dispa Name	nen			I.12. Place of destination Name					
Ă	Address				Address					
τI	Approval Number	r			Approval Number					
Paı	Country		ISO Code		Country ISO Code					
	I.13. Place of loadi	ng			I.14. Date and time of departure					
	Name	0								
	Address									
	Approval Number	r								
	Country		ISO Code							
	I.15. Means of Trai	nsport			I.16. Transporter					
	Mode	International	Identification		Name					
		transport document			Address					
					Activity ID					
					Country	ISO Code				
					I.17. Accompanying documents					
					Accompanying document reference					
					Date of issue					
					Country					
					Place of issue					
	I.18. Transport cor	nditions		,						
	Ambient 🗆		Chille	d	Frozen 🗆					
	I.19. Container No	/ Seal No								
	I.20. Certified as									
	Further keeping [Confined establish	iment 🗆	Exhibition \Box					
	I.21. For transit th	rough a third coun	itry							
	Third country				ISO Code					
	Exit point				BCP code					
	Entry point	naar ah Maraahan Sta	ta(a)		BCP code					
	I.22. For transit th	rougn Member Sta			I.23. For export					
	Member State		ISO Code		Third countryISO CodeExit pointBCP code					
	I.24. Estimated jou	Irney time			I.25. Journey Log					
	I.27. Total quantity	-			I.28. Total gross weight					
I.30. Description of consignment										
		f consignment								
		_								
	I.30. Description o	LS								
	I.30. Description o 1. 01 LIVE ANIMA 0106 Other live Birds:	LS animals								
	I.30. Description o 1. 01 LIVE ANIMA 0106 Other live Birds: 010632 Psit	LS animals ttaciformes (includ	ling parrots, parake							
	I.30. Description o 1. 01 LIVE ANIMA 0106 Other live Birds: 010632 Psit 0106320	LS animals ttaciformes (includ 0 Psittaciformes (ir	ncluding parrots, pa	rakeets, macaws	and cockatoos)	er Quantity				
	I.30. Description o 1. 01 LIVE ANIMA 0106 Other live Birds: 010632 Psit	LS animals ttaciformes (includ 0 Psittaciformes (ir		rakeets, macaws		er Quantity				

_	KOI LAN					establistilleri					
	II. Health info	ormation									
I, the undersigned official veterinarian, hereby certify, that:											
	II.1.	.The anima	als(1) in the	consignmen	nt described i	n Part I meet the following r	requirements:				
		II.1.1.		ïned establi ion (EU) 201		spatch is approved in accord	ance with Articles 97 and 99				
r al l II. Cel ull'autol		II.1.2.	listed in An examination	nnex of Com on, or wher 48 hour per	nmission Imp e this is not p	s or symptoms of diseases, in particular relevant diseases plementing Regulation (EU) 2018/1882, during the clinical possible, a clinical inspection, which was carried out departure of the consignment, on (insert					
מדרדי	II.2.	-	to official in uirements:	nformation,	animals in th	ne consignment described in	Part I meet the following				
ÿ		II.2.1.		They come from a confined establishment that is not subject to movement restrictions affecting the animals to be moved.							
	(2)(3) 🗆 either	[II.2.2.	(serotypes	1-24), wher	e no case of i	•	rus (serotypes 1-24) has beer				
			vaccinated 60 day per	bes 1-24), where no case of infection with bluetongue virus (serotypes 1-24) has ned during the last 24 months in the targeted animal population and have not h ted with a live vaccine against infection with bluetongue virus (serotypes 1-24) period before the date of movement and the requirements laid down in Article (b) or (c) or Article 32(2) of Commission Delegated Regulation (EU) 2020/688 a .]							
	(2)(3) 🗆 and/or	[II.2.2.	They originate from a Member State or a zone covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 are fulfilled, and they								
	(2)	□ either	[II.2.2.1.	bluetongu	-		ly free from infection with h Article 40(3) of Commissio				
		(2)	🗆 either	[II.2.2.1.1.	for at least (50 days prior to the date of n	novement]]				
		(2)	□ and/or		for at least 2 subjected to samples col animal into	28 days prior to the date of n a serological test, with nega lected at least 28 days follow	novement and have been ative results, carried out on ring the entry date of the easonally free from infectior				
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at the Member	•	sults, carried out on samples entry date of the animal into				
	(2)	□ and/or	[II.2.2.2.	place of de			during transportation to the gainst attacks by vectors in a				
		(2)	🗆 either	[II.2.2.2.1.	for at least (60 days prior to the date of n	novement]] .				
		(2)	□ and/or	[II.2.2.2.2.	subjected to samples col	28 days prior to the date of n a serological test, with nega lected at least 28 days follow nent of the period of protect	tive results, carried out on ring the date of the				
		(2)	□ and/or	[II.2.2.2.3.	subjected to collected at	•	sults, carried out on samples late of the commencement o				
	(2)	□ and/or	[II.2.2.3.			gainst those serotypes from were reported during the p					

	II. Health info	ormation								
				State or zo	ne and are w	vithin the im	munity period g	uaranteed in the		
			 State or zone and are within the immunity period guaranteed in the specifications of the vaccine and □ either [II.2.2.3.1. have been vaccinated more than 60 days before the date of 							
		(2)	🗆 either	[II.2.2.3.1.	have been v movement]		ore than 60 days	s before the date of	-	
Part II: Certification		(2)	□ and/or	[II.2.2.3.2.	PCR test, wi	ith negative i	results on sample	d vaccine and subj es collected at least e specifications of t	14 days	
rt II: Ceri	(2)	□ and/or	[II.2.2.4.	specific an	have been subjected with positive results to a serological test able to detect specific antibodies against all serotypes 1-24 of infection with bluetongue virus reported during the past 2 years in that Member State or zone and					
Pai		(2)	□ either	[II.2.2.4.1.			oeen carried out of movement]]	on samples collect	ed at least	
		(2)	□ and/or	[II.2.2.4.2.	 the serological test has been carried out on samples collected at least 30 days before the date of the movement and the animal has been subjected to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of movement;]] 					
	(2)(3) 🗆 and/or	[II.2.2.	virus (sero bluetongu	otypes 1-24) e virus (serc	ate from a Member State or a zone neither free from infection with bluetongue ypes 1-24) nor covered by the eradication programme for infection with virus (serotypes 1-24) and the requirements laid down in Article 32(1)(a), (b) or e 32(2) of Delegated Regulation (EU) 2020/688 are fulfilled, and they					
	(2)	□ either	[II.2.2.1.	place of de		d have been	kept protected a	luring transportati gainst attacks by ve		
		(2)	🗆 either	[II.2.2.1.1.	for at least	60 days prio	r to the date of m	novement]]		
		(2)	□ and/or	[II.2.2.1.2.	subjected to samples col	o a serologica llected at lea	al test, with nega st 28 days follow	novement and have tive results, carried ing the date of the ion against attacks	d out on	
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at	o a PCR test, least 14 day	with negative re	novement and have sults, carried out or ate of the commen by vectors;]]]	n samples	
	(2)	□ and/or	[II.2.2.2.	establishm centred on requireme	nent situated a the establish ents laid down	in a Membe hment, wher n in Sections	r State or in an a re surveillance in a 1 and 2 of Chap	o departure in an rea of at least 150 k compliance with t ter 1 of Part II of Ar d out during that p	he nnex V to	
		(2)	□ either	[II.2.2.2.1.	24 of infect the past 2 y place where	ion with blue ears in an ar e the animal	etongue virus wh ea of at least 150 s were kept and	st those serotypes f nich were reported) km radius centred are within the imm of the vaccine and	during l on the	
			(2)	🗆 either	[II.2.2.2.1.1.	have been v of moveme		than 60 days befor	e the date	
			(2)	□ and/or	[II.2.2.2.1.2.	have been v subjected to collected at	vaccinated with a of a PCR test, with	an inactivated vacc negative results on er the onset of the ne vaccine;]]]]	n samples	
		(2)	□ and/or	[II.2.2.2.2.	24 of infect the past 2 y	ion with blue ears in an ar	etongue virus wł	ist those serotypes nich were reported) km radius centred	during	

II. Booth information (2) • either [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 50 days before the date of movement]] (2) • or [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected at lease 30 days before the date of the movement and the application of the analysis of the movement is and the subjected with positive results carried out on samples collected at lease 30 days before the date of movement and the date of movement and the set of origin authorised novement is antimals to another Member State of origin authorised novement is antimis to another Member State of control the Commission and the other Member State of action in factorial state state state. In the Member State of a control (EU) 2020(689 and the competent authority of the Member State of action is referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (c)) (2) either III.2.2.1. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and <td< th=""><th>_</th><th colspan="6"></th><th></th><th><u> </u></th></td<>	_								<u> </u>	
Image: Second			II. Health info	ormation						
1000000000000000000000000000000000000	rtification				(2)	∘ either	[II.2.2.2.2.1.	a serological test carried out on samples collected at lea		
(2) □ either [II.2.2.1.] with the status free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State state state submitted subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ either [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and (2) □ and/or [II.2.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State stat such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to		eruncation			(2)	0 or	[II.2.2.2.2.2.	a serological test carried out on samples collected at lea 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of		
the Member State of destination has informed the commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020(688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled.]]] (2) and/or [II.2.2.2.4) with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of Astat Such Novement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (2) either [II.2.2.2.2] point 5 of Section		Part II: C		[II.2.2.	Part II of A State of or	nnex V to Regulation (EU) 2020/689 and the competent authority of the I igin authorised movement of those animals to another Member State or				
L Delegated Regulation, and (2) and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States that such movement is authorised subject to the conditions referred to in Article 32(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(688 and (2) either [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and			(2)	□ either	[II.2.2.1.	the Memb Member S referred to	er State of de tates that suc	estination has informed the Commission and the other ch movement is authorised subject to the conditions	1	
(2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.3.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [(2)	□ either	[II.2.2.1.1.				
Part of the second s				(2)	□ and/or	[II.2.2.1.2.	-	-		
Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation are fulfilled;]]] (2) and/or </td <th></th> <td></td> <td></td> <td>(2)</td> <td>□ and/or</td> <td>[II.2.2.1.3.</td> <td></td> <td></td> <td></td>				(2)	□ and/or	[II.2.2.1.3.				
32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the o				(2)	□ and/or	[II.2.2.1.4.	-	-		
 (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ either [II.2.2.2.1] point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.2] point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.3] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) □ and/or [II.2.2.3] neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State stat such movement is authorised (2) □ either [II.2.2.3.] without any conditions, and (2) □ either [II.2.2.3.] without any conditions, and (2) □ and/or [II.2.3.2.] subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/688, and 							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements		
Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.3.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3.1. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commi			(2)	□ and/or	[II.2.2.2.	(serotypes Commission subject to	1-24) and the ot the condition	e Member State of destination has informed the her Member States that such movement is authorised is referred to in Article 43(2)(a), (b) and (c) of Delegated		
Cancel and/or [II.2.2.3.] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and Cancel C				(2)	□ either	[II.2.2.2.1.				
 (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	\Box and/or	[II.2.2.2.2.				
 Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	\Box and/or	[II.2.2.2.3.				
 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	□ and/or	[II.2.2.2.4.	-	-		
 by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) □ either [II.2.2.3.1. without any conditions, and (2) □ and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements		
(2)			(2)	□ and/or	[II.2.2.3.	by the erac 24) and the	dication prog e Member St	gramme for infection with bluetongue virus (serotypes 1 ate of destination has informed the Commission and the	l-	
(2)				(2)	🗆 either	[II.2.2.3.1.	without any	y conditions, and		
							subject to th	he conditions referred to in point 5 of Section 1 of Chapt	er	
				(2)	□ and/or	[II.2.2.3.3.			er	

	II. Health info	rmation						(
					2 of Part II o	f Annex V to Delegated Re	gul	ation (EU) 2020/689, and	
			e conditions referred to in point 7 of Section 1 of Chapter f Annex V to Delegated Regulation (EU) 2020/689, and						
- -	2 of Part II of Ann				conditions referred to in point 8 of Section 1 of Chapter Annex V to Delegated Regulation (EU) 2020/689, and				
Part II: Certification					32(2) of Dele	nents laid down in Article gated Regulation (EU) 202 A Article 33 of that Delegat	20/6	88 and the requirements	
မီ	II.3 To the best of my knowledge and as declared by the operator:								
Part II		II.3.1.				patch there are no abnor nimals to be moved.	mal	mortalities with an	
		II.3.2.		The animals have not been in contact with animals which are subject to movement restrictions referred to in Point II.2.1., or with animals of a lower health status.					
		II.3.3. Based on the results of the surveillance plan of the confined establishment, the animals do not pose a significant risk at the confined establishment of destination for the spread of diseases for which they are listed.							
	II.4.	-	ents are ma 1 (EU) 2020/6	-	ort the consig	gnment in accordance with	h A	rticle 4 of Delegated	
	II.5.	animals, th		10 days for				nsport by waterway/sea of ded by the duration of the	
	(2) either \circ [II.6 Bovine animals from vaccination zone I in relation to emergency protective vaccination again lumpy skin disease, in compliance with Article 13(2) of, and Annex IX, Part 3, point (3.1), to Commission Delega Regulation (EU) 2023/361.]								
	skin diseas		iance with A			lation to emergency protec x IX, Part 3, point (3.2), to (e vaccination against lumpy nmission Delegated	
Animal welfare attestation									
At the time of inspection, the animals covered by this health certificate were fit to be transported in accert with the provisions of Council Regulation (EC) No 1/2005 on the intended journey due to start on (insert date).									
	Notes:								
	In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Irela from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland / Northern Ireland in conjunction with Annex 2 to that Protocol, references to European Unio in this certificate include the United Kingdom in respect of Northern Ireland.								
	This animal health certificate shall be completed according to the notes for the completion of certificates provide for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.							on of certificates provided	
Part I:									
	Box reference I.11:	reference of Regulation (EU) 2016/429.							
	Box reference I.12:		lestination": lation (EU) 2		confined estal	plishment approved in acc	cord	lance with Articles 97 and	
	Part II:								
(1) There can be one or more animals in the consignment.									
	(2)	Delete if n	ot applicabl	e.					

	II. Health information		
	(3) Only in case of animals belonging to the famil Giraffidae, Moschidae or Tragulidae.	ies Antilocapridae, Bovidae, C	amelidae, Cervidae,
	Certifying Officer/Official veterinarian		
	Name (in capital letters)	Qualification and title	
	Date of signature	Signature	
Part II: Certification	Stamp		
ica			
irtif			
: Ce			
τII			
Par			